Significant Progress in Duchenne Muscular Dystrophy Treatment: Brogidirsen's 4.5-Year Clinical Data Unveiled NS Pharma's presentation at the 2026 MDA Conference reveals impressive 4.5-year clinical trial results for Brogidirsen in treating DMD, showcasing long-term efficacy and safety.

Significant Progress in Duchenne Muscular Dystrophy Treatment: Brogidirsen's 4.5-Year Clinical Data Unveiled #USA #NS_Pharma #Paramus #Duchenne_Muscular_Dystrophy #Brogidirsen

Brogidirsen Clinical Trial Results Offer Hope for DMD Treatment at 2025 World Muscle Society Congress NS Pharma presented promising 3.5-year clinical trial data for brogidirsen as a treatment for Duchenne muscular dystrophy at the 2025 World Muscle Society Congress.

Brogidirsen Clinical Trial Results Offer Hope for DMD Treatment at 2025 World Muscle Society Congress #None #NS_Pharma #Paramus #Duchenne_Muscular_Dystrophy #Brogidirsen

FDA Approves Orphan Drug Status for NS-051/NCNP-04 to Combat Duchenne Muscular Dystrophy NS Pharma has received Orphan Drug Designation from the FDA for NS-051/NCNP-04, aimed at treating Duchenne muscular dystrophy through exon 51 skipping therapy.

FDA Approves Orphan Drug Status for NS-051/NCNP-04 to Combat Duchenne Muscular Dystrophy #United_States #NS_Pharma #Paramus #Duchenne_Muscular_Dystrophy #NS-051

NS Pharma's NS-229 Receives Fast Track Designation for Rare Autoimmune Disease Treatment NS Pharma's NS-229 has received Fast Track designation from the FDA for treating eosinophilic granulomatosis with polyangiitis, a rare autoimmune condition.

NS Pharma's NS-229 Receives Fast Track Designation for Rare Autoimmune Disease Treatment #United_States #NS_Pharma #FDA_Fast_Track #Paramus,_NJ #NS-229

NS Pharma Strengthens Commitment to Rare Disease Solutions with Boston Children's Hospital Alliance NS Pharma has partnered with Boston Children's Hospital to innovate therapies for rare diseases, enhancing patient treatment options through collaborative research.

NS Pharma Strengthens Commitment to Rare Disease Solutions with Boston Children's Hospital Alliance #United_States #NS_Pharma #Paramus #Nippon_Shinyaku #Boston_Children's

FDA Accepts Application for Breakthrough Treatment of Mucopolysaccharidosis II The FDA has accepted a Biologics License Application for RGX-121, a groundbreaking gene therapy for treating Mucopolysaccharidosis II, promising new hope for affected families.

FDA Accepts Application for Breakthrough Treatment of Mucopolysaccharidosis II #United_States #NS_Pharma #Paramus #RGX-121 #Mucopolysaccharidosis_II

FDA Approves Orphan Drug Status for NS-229 in Treating Rare Disease EGPA The FDA has designated NS-229 as an Orphan Drug, aimed at treating eosinophilic granulomatosis with polyangiitis (EGPA) and providing seven years of market exclusivity.

FDA Approves Orphan Drug Status for NS-229 in Treating Rare Disease EGPA #United_States #NS_Pharma #Paramus #Orphan_Drug #EGPA

NS Pharma Receives FDA Acceptance for Duchenne Muscular Dystrophy Treatment: A Hope for Families NS Pharma's acceptance from the FDA for its cell therapy deramiocel marks a significant advancement in treating Duchenne muscular dystrophy, offering hope to affected families.

NS Pharma Receives FDA Acceptance for Duchenne Muscular Dystrophy Treatment: A Hope for Families #USA #NS_Pharma #Paramus #Duchenne_Muscular_Dystrophy #deramiocel

NS Pharma's Leadership Change: Fostering Innovation in Rare Disease Therapies NS Pharma announces new leadership in its Commercial division aimed at enhancing growth in rare disease therapies, including VILTEPSO.

NS Pharma's Leadership Change: Fostering Innovation in Rare Disease Therapies #USA #NS_Pharma #VILTEPSO #Donald_Foy #Paramus